Timothée Olivier, MD
@Timothee_MD
Followers
3K
Following
3K
Media
414
Statuses
2K
Oncology (sarcoma, H&N, CUP). EBM, Health Policy @HUG_ge (Geneva), @vkprasadlab (UCSF). Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.
Genève, Suisse
Joined December 2021
RT @CrozrX: @brunolarvol @onder_haka2124 @dr_yakupergun @Larvol @ghosalsandeep An invaluable resource for oncology field is project by @Tim….
0
1
0
Sounds great @chadinabhan!.Looking forward to it!. I hope the questions of censoring will be adressed!. "Can I confidently say to patients that a 3-year structured exercise program may save their lives? The CHALLENGE trial".
The “CHALLENGE” trial presented at @ASCO #ASCO25 & pub in @NEJM made a lot of noise - exercise improves OS?.The PI himself, Dr. Chris Booth visits with #HealthcareUnfiltered EXPRESS to explain the study and its findings. Full video tomorrow - not to be missed.
1
0
4
Some overlapping questions .See here (+ slide below).
Agree with @DrYukselUrun this is expected to be paradigm shifting in this population! Can’t wait to see data! A few questions to ask preemptively:.1. % of pts who received adj Nivo in control group .2. % histology subtype component.3. Subsequent therapies in mUC.4. F/u duration.
0
0
9
RT @Wafa_Asha: Just finished Malignant by @VPrasadMDMPH, without doubt one of the most powerful books I’ve read and a must-read for every o….
0
4
0
Recent @WSJ articles are deeply problematic, Ccongrats again @kevinnbass for unveiling it!. It feels like “When wolves are cornered, they show their teeth.”. Keep the great work and leadership @DrMakaryFDA !.
Wall Street Journal has launched another dumb attack--this time at Trump FDA appointee Marty Makary. This article is filled with wild representations. I explain in depth below. I also explain the role of science in medicine and why WSJ Editorial Board is not smart.
3
2
18
0
1
0
RT @mkhashki: Honored to host Dr. @Timothee_MD as the first guest in our clinical trials in oncology webinar series. Dr. Olivier covered ke….
0
6
0
0
1
0
Update, thanks to @g_mountzios 🙏 and to @Amgen, I got this reply: ."Thank you for your comment. The authors confirm that all patients randomized in DeLLphi-304 have been accounted for in the efficacy analysis according to the statistical analysis plan. In particular,
3
6
19
Great coverage from @gekaminsky and @TheFP about Laura Loomer, thank you!. “A lot of us strongly suspect that Sarepta helped fuel her crusade against Vinay,” a White House official told me. Another Trump administration official said, “I don’t see how it’s possible she isn’t.
Laura Loomer says she is motivated by her loyalty to Trump, but White House staffers tell Gabe Kaminsky that ‘there is widespread understanding here that she’s not guided entirely by loyalties to the president.’
2
3
20
RT @TheFP: Laura Loomer says she is motivated by her loyalty to Trump, but White House staffers tell Gabe Kaminsky that ‘there is widesprea….
thefp.com
Laura Loomer says she is motivated by her loyalty to Trump, but White House staffers tell Gabe Kaminsky that ‘there is widespread understanding here that she’s not guided entirely by loyalties to the...
0
7
0
RT @Timothee_MD: Academic read of the day!. Crossover in oncology? . A concise, open-access, 2-page paper clearly framing when it is is des….
0
20
0
RT @Timothee_MD: Such curves (separating dramatically so early) likely indicate selection bias: patients who come for morning CAR-T may sim….
0
8
0
In the famous Chinese RCT, recently presented at #ASCO25, curves are much more plausible. Needs replication of course, see my take on this: .@StephenVLiu .2/2
0
0
5
Such curves (separating dramatically so early) likely indicate selection bias: patients who come for morning CAR-T may simply be in better conditions. A classic pitfall well described by @ManniMD1 and @VPrasadMDMPH in this JAMA IM paper : 1/2
1/ My first time tweeting preprint since March 2020. Analysis of >600 CAR-T recipients from two 🇺🇸 time zones. Earlier infusions (before 3pm) seem to be better! 😳. ⚠️ Still needs peer review. I don't see breakdown of specific CAR products by ≤2:59p vs ≥3:00p, for instance.
6
8
50